Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

被引:183
作者
Lussier, Danielle M. [1 ,2 ]
Johnson, John L. [2 ]
Hingorani, Pooja [3 ]
Blattman, Joseph N. [1 ,2 ]
机构
[1] Arizona State Univ, Mol & Cellular Biol Grad Program, Tempe, AZ 85281 USA
[2] Arizona State Univ, Ctr Infect Dis & Vaccinol, BioDesign Inst, Tempe, AZ 85287 USA
[3] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ 85016 USA
关键词
T-CELLS; MONOCLONAL-ANTIBODIES; REGULATORY T; PD-1; CTLA-4; ACTIVATION; PATHWAY; TUMORS; B7-H1; SURVEILLANCE;
D O I
10.1186/s40425-015-0067-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Osteosarcoma is one of the most common bone cancers in children. Most patients with metastatic osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have previously shown that PD-1 limits the efficacy of CTL to mediate immune control of metastatic osteosarcoma in the K7M2 mouse model of pulmonary metastatic disease and that blockade of PD-1/PD-L1 interactions can partially improve survival outcomes by enhancing the function of osteosarcoma-specific CTL. However, PD-1/PD-L1 blockade-treated mice eventually succumb to disease due to selection of PD-L1 mAb-resistant tumor cells. We investigated the mechanism of tumor cell resistance after blockade, and additional combinational therapies to combat resistance. Methods: We used an implantable model of metastatic osteosarcoma, and evaluated survival using a Log-rank test. Cellular analysis of the tumor was done post-mortem with flow cytometry staining, and evaluated using a T-test to compare treatment groups. Results: We show here that T cells infiltrating PD-L1 antibody-resistant tumors upregulate additional inhibitory receptors, notably CTLA-4, which impair their ability to mediate tumor rejection. Based on these results we have tested combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade in the K7M2 mouse model of metastatic osteosarcoma and show that this results in complete control of tumors in a majority of mice as well as immunity to further tumor inoculation. Conclusions: Thus, combinational immunotherapy approaches to block additional inhibitory pathways in patients with metastatic osteosarcoma may provide new strategies to enhance tumor clearance and resistance to disease.
引用
收藏
页数:11
相关论文
共 46 条
[1]   Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].
Akbay, Esra A. ;
Koyama, Shohei ;
Carretero, Julian ;
Altabef, Abigail ;
Tchaicha, Jeremy H. ;
Christensen, Camilla L. ;
Mikse, Oliver R. ;
Cherniack, Andrew D. ;
Beauchamp, Ellen M. ;
Pugh, Trevor J. ;
Wilkerson, Matthew D. ;
Fecci, Peter E. ;
Butaney, Mohit ;
Reibel, Jacob B. ;
Soucheray, Margaret ;
Cohoon, Travis J. ;
Janne, Pasi A. ;
Meyerson, Matthew ;
Hayes, D. Neil ;
Shapiro, Geoffrey I. ;
Shimamura, Takeshi ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Hammerman, Peter S. ;
Dranoff, Glenn ;
Wong, Kwok-Kin .
CANCER DISCOVERY, 2013, 3 (12) :1355-1363
[2]   B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells [J].
Azuma, Takeshi ;
Yao, Sheng ;
Zhu, Gefeng ;
Flies, Andrew S. ;
Flies, Sarah J. ;
Chen, Lieping .
BLOOD, 2008, 111 (07) :3635-3643
[3]   Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion [J].
Blank, Christian ;
Mackensen, Andreas .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :739-745
[4]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[5]   Osteosarcoma Lung Metastases Detection and Principles of Multimodal Therapy [J].
Carrle, Dorothe ;
Bielack, Stefan .
PEDIATRIC AND ADOLESCENT OSTEOSARCOMA, 2009, 152 :165-+
[6]   B7 family checkpoint regulators in immune regulation and disease [J].
Ceeraz, Sabrina ;
Nowak, Elizabeth C. ;
Noelle, Randolph J. .
TRENDS IN IMMUNOLOGY, 2013, 34 (11) :556-563
[7]   PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].
Curran, Michael A. ;
Montalvo, Welby ;
Yagita, Hideo ;
Allison, James P. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280
[8]  
D'Angelo S. P., 2014, Sarcoma, V2014, P391967, DOI 10.1155/2014/391967
[9]   Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice [J].
Dieudonne, Francois-Xavier ;
Marion, Allison ;
Marie, Pierre J. ;
Modrowski, Dominique .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (10) :2118-2129
[10]  
Dong H, 2002, NAT REV IMMUNOL, V2, P545